## Shrimati Shetty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3153321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Novel RASGRP2 variants in platelet function defects: Indian study. British Journal of Haematology, 2022, , .	2.5	1
2	A rare case of Glanzmann's thrombasthenia and factor VII deficiency due to a combination of pathogenic and nonâ€pathogenic gene variants. Haemophilia, 2020, 26, e26-e27.	2.1	1
3	Congenital PAI-1 deficiency results in psoas hematoma in an Indian patient. Thrombosis Research, 2020, 190, 35-38.	1.7	0
4	Differential response to FEIBA is strongly associated with the prothrombotic microparticles. Blood Cells, Molecules, and Diseases, 2020, 84, 102441.	1.4	1
5	Triple jeopardy: A case of Glanzmann's thrombasthenia with anti-GPIIb-IIIa antibodies and HPA incompatibility resulting in stillbirth. Thrombosis Research, 2019, 181, 141-144.	1.7	6
6	A rare cause of bleeding in two Indian families with congenital alphaâ€2â€antiplasmin deficiency. Haemophilia, 2019, 25, e370-e372.	2.1	0
7	Prediction of preeclampsia using combination of biomarkers at 18–23â€⁻weeks of gestation: A nested case-control study. Pregnancy Hypertension, 2019, 17, 20-27.	1.4	5
8	Anti-factor VIII inhibitors against A2 and C2 domains in hemophilia A patients from India. Blood Cells, Molecules, and Diseases, 2019, 75, 11-12.	1.4	0
9	A novel p.Pro353His <i>SERPINC1</i> mutation in the thrombinâ€binding region affecting stability of Antithrombin molecule in an extended Omani family. International Journal of Laboratory Hematology, 2018, 40, e49-e51.	1.3	0
10	Microparticles as prognostic biomarkers in dengue virus infection. Acta Tropica, 2018, 181, 21-24.	2.0	15
11	Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 353-359.	1.7	18
12	Role of lupus anticoagulants in immediate acting inhibitor positivity in congenital haemophilia A patients. Thrombosis Research, 2018, 172, 29-35.	1.7	2
13	Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency. Blood Coagulation and Fibrinolysis, 2017, 28, 105-106.	1.0	2
14	Management of pregnancy in dysfibrinogenemia cases. Blood Coagulation and Fibrinolysis, 2017, 28, 91-93.	1.0	7
15	Dysfunctional fibrinolysis and cerebral venous thrombosis. Blood Cells, Molecules, and Diseases, 2017, 65, 51-55.	1.4	4
16	Investigation of Plasminogen Activator Inhibitorâ€1 ( <scp>PAI</scp> â€1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A caseâ€control study. European Journal of Haematology, 2017, 99, 249-254.	2.2	17
17	Mortality caused by intracranial bleeding in non-severe hemophilia A patients: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 1709-1710.	3.8	1
18	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 1708-1708.	3.8	0

#	Article	IF	CITATIONS
19	A novel homozygous frameshift mutation in Exon 7 of the <i>ADAMTS13</i> gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report. Transfusion, 2017, 57, 2712-2714.	1.6	3
20	A de novo factor <scp>VIII</scp> mutation in a haemophilia B family leading to combined deficiency of factor <scp>VIII</scp> and <scp>IX</scp> . Haemophilia, 2017, 23, e477-e479.	2.1	2
21	Combination of copeptin, placental growth factor and total annexin V microparticles for prediction of preeclampsia at 10–14 weeks of gestation. Placenta, 2017, 58, 67-73.	1.5	25
22	Indian Bombay phenotype: it is different!. Blood Transfusion, 2017, 15, 74-76.	0.4	1
23	Congenital macrothrombocytopenia is a heterogeneous disorder in India. Haemophilia, 2016, 22, 570-582.	2.1	10
24	Re: Does lowâ€molecularâ€weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of earlyâ€onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results LMWH influencing fetal growth. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 844-844.	2.3	0
25	First trimester prenatal diagnosis of severe <scp>FXIII</scp> deficiency. Haemophilia, 2016, 22, e443-4.	2.1	4
26	Possible selection of host folate pathway gene polymorphisms in patients with malaria from a malaria endemic region in North East India. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 294-298.	1.8	4
27	Clinical and molecular epidemiology of factor XI deficiency in India. Thrombosis Research, 2016, 147, 85-87.	1.7	8
28	Bengal macrothrombocytopenia is not totally an innocuous condition. Blood Cells, Molecules, and Diseases, 2016, 60, 3-6.	1.4	5
29	Decrease in circulating percentage platelet microparticles during pregnancy—a different perspective. Annals of Hematology, 2016, 95, 533-534.	1.8	0
30	Why should hemophilia B be milder than hemophilia A?. Haematologica, 2016, 101, e213-e213.	3.5	4
31	A common missense variant in exon 5 of antithrombin gene (SERPINC1) in Indian patients with thrombosis. Thrombosis Research, 2016, 143, 1-2.	1.7	5
32	Prediction of smallâ€forâ€gestationalâ€age at 35–37 weeks of gestation: too late for management?. Ultrasound in Obstetrics and Gynecology, 2016, 47, 385-385.	1.7	0
33	Annexin <scp>A</scp> 5 levels or circulating microparticles: what we see depends mainly on what we look for. Journal of Internal Medicine, 2016, 279, 608-608.	6.0	1
34	Comment on Salomon et al. Gestational Diabetes Mellitus Is Associated With Changes in the Concentration and Bioactivity of Placenta-Derived Exosomes in Maternal Circulation Across Gestation. Diabetes 2016;65:598–609. Diabetes, 2016, 65, e24-e25.	0.6	4
35	Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients: Identification of fourteen novel mutations. Blood Cells, Molecules, and Diseases, 2016, 57, 81-84.	1.4	12
36	Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. Critical Reviews in Oncology/Hematology, 2016, 99, 129-133.	4.4	20

#	Article	IF	CITATIONS
37	Could procoagulant cell–derived microparticles have a more crucial role in pregnancy complications rather than exosomes?. American Journal of Obstetrics and Gynecology, 2016, 214, 765-766.	1.3	1
38	F8 gene mutation profile in Indian hemophilia A patients: Identification of 23 novel mutations and factor VIII inhibitor risk association. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2016, 786, 27-33.	1.0	8
39	Does consumption of platelet-derived microparticles in the fibrin clot explain the decrease in their percentage during pregnancy?. Blood Cells, Molecules, and Diseases, 2016, 57, 115-117.	1.4	0
40	Preeclampsia: simplified or still miles to go?. American Journal of Obstetrics and Gynecology, 2016, 214, 668-669.	1.3	1
41	A simple clot based assay for detection of procoagulant cell-derived microparticles. Clinical Chemistry and Laboratory Medicine, 2016, 54, 799-803.	2.3	13
42	Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors. Immunology Letters, 2016, 169, 93-97.	2.5	1
43	Differential expression of genes involved in Bengal macrothrombocytopenia (BMTCP). Blood Cells, Molecules, and Diseases, 2015, 55, 410-414.	1.4	5
44	Spectrum of mutations in Indian patients with fibrinogen disorders and its application in genetic diagnosis of the affected families. Haemophilia, 2015, 21, e519-e523.	2.1	5
45	Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 1737-1738.	3.8	Ο
46	Prenatal diagnosis in a family with purfura fulminans. Blood Coagulation and Fibrinolysis, 2015, 26, 350.	1.0	0
47	Is peripheral blood corin level clinically relevant for prediction of pre-eclampsia?. Ultrasound in Obstetrics and Gynecology, 2015, 46, 380-380.	1.7	2
48	Promising prognostic markers of Preeclampsia: New avenues in waiting. Thrombosis Research, 2015, 136, 189-195.	1.7	26
49	Effect of anticoagulant therapy on cell-derived microparticles and pregnancy outcome in women with pregnancy loss. British Journal of Haematology, 2015, 171, 892-896.	2.5	12
50	Novel therapeutic approaches for haemophilia. Haemophilia, 2015, 21, 152-161.	2.1	17
51	Challenges and open issues in the management of acquired hemophilia A (AHA). Blood Cells, Molecules, and Diseases, 2015, 54, 275-280.	1.4	9
52	Inherited and acquired thrombophilia in Indian women experiencing unexplained recurrent pregnancy loss. Blood Cells, Molecules, and Diseases, 2015, 55, 200-205.	1.4	10
53	Paradoxical Bleeding and Thrombosis in a Patient With Afibrinogenemia and Fibrinogen Mumbai Mutation. American Journal of Clinical Pathology, 2015, 143, 755-757.	0.7	9
54	Sense, missense, and nonsense: a novel mechanism of premature termination codon (PTC) mutation in a severe von Willebrand disease (VWD) patient. Annals of Hematology, 2015, 94, 1409-1410.	1.8	0

#	Article	IF	CITATIONS
55	Prenatal diagnosis in a haemophilia carrier with triplet pregnancy. Haemophilia, 2015, 21, e228-30.	2.1	Ο
56	Genetic Heterogeneity in a Large Cohort of Indian Type 3 von Willebrand Disease Patients. PLoS ONE, 2014, 9, e92575.	2.5	14
57	Genetic thrombophilia and natural anticoagulants: importance of polymorphisms within and outside the genes. Haematologica, 2014, 99, e30-e30.	3.5	Ο
58	Glanzmann's thrombasthenia – newer treatment options. Expert Opinion on Orphan Drugs, 2014, 2, 5-10.	0.8	1
59	Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia, 2014, 20, 575-581.	2.1	32
60	Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study: comment. Journal of Thrombosis and Haemostasis, 2014, 12, 1377-1378.	3.8	0
61	Paternal factor V Leiden and recurrent pregnancy loss: a new concept behind fetal genetics?: comment. Journal of Thrombosis and Haemostasis, 2014, 12, 1758-1759.	3.8	1
62	Acquired and Heritable Thrombophilia in Indian Patients With Pediatric Deep Venous Thrombosis (DVT). Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 573-576.	1.7	4
63	A specific and sensitive activated partial thromboplastin time (APTT)-based factor VIII inhibitor screening assay. Clinical Chemistry and Laboratory Medicine, 2014, 52, e39-41.	2.3	3
64	Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients. Blood Cells, Molecules, and Diseases, 2014, 53, 161-163.	1.4	4
65	An atypical manifestation of acquired von Willebrand syndrome (AVWS) associated with systemic lupus erythematosus (SLE). Annals of Hematology, 2014, 93, 173-175.	1.8	6
66	Novel genetic abnormalities in Bernard-Soulier syndrome in India. Annals of Hematology, 2014, 93, 381-384.	1.8	9
67	The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 356-363.	0.6	15
68	Factor V Leiden mutation modulates the bleeding phenotype in warfarin sensitive patients. Thrombosis Research, 2014, 133, 955-956.	1.7	0
69	Prenatal diagnosis in severe von Willebrand disease families from India using combination of phenotypic and genotypic assays. Prenatal Diagnosis, 2014, 34, 377-381.	2.3	6
70	The association of <scp>HLAâ€DRB1</scp> and <scp>HLAâ€DQB1</scp> alleles with the development of factor <scp>VIII</scp> inhibitors in severe haemophilia A patients in India. Tissue Antigens, 2014, 84, 235-237.	1.0	5
71	Delayed Vitamin K Deficiency Related Bleeding: Is it Genetically Linked?. Indian Journal of Pediatrics, 2014, 81, 310-311.	0.8	0
72	VKORC1 and CYP2C9 genotype distribution in Asian countries. Thrombosis Research, 2014, 134, 537-544.	1.7	44

#	Article	IF	CITATIONS
73	Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy. European Journal of Clinical Pharmacology, 2013, 69, 293-294.	1.9	4
74	A common founder mutation p.P2063S in exon 36 of VWF in 11 unrelated Indian von Willebrand disease (VWD) families. Annals of Hematology, 2013, 92, 1147-1148.	1.8	7
75	Factor VIII haplotypes in severe hemophilia A patients in India. Annals of Hematology, 2013, 92, 999-1000.	1.8	4
76	Polymorphisms of warfarin metabolizing enzymes in an Indian population. Blood Cells, Molecules, and Diseases, 2013, 51, 203.	1.4	0
77	Role of microparticles in recurrent miscarriages and other adverse pregnancies: a review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 123-129.	1.1	10
78	Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population. European Journal of Pharmacology, 2013, 710, 80-84.	3.5	27
79	Prevalence of factor V G1691A, factor II G20210A, methylenetetrahydrofolate reaductase C677T and endothelial protein C receptor 23Âbp insertion polymorphisms in indigenous population of Nepal. Annals of Hematology, 2013, 92, 261-262.	1.8	2
80	Possible impact of factor V Leiden genotype on warfarin induced bleeding. Indian Journal of Human Genetics, 2013, 19, 377.	0.7	0
81	Molecular pathology of Bernard–Soulier syndrome in Indian patients. Platelets, 2013, 24, 571-573.	2.3	5
82	Warfarin pharmacogenetics: How close are we to clinical practice?. Indian Journal of Human Genetics, 2013, 19, 277.	0.7	1
83	The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles: a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 1784-1785.	3.8	1
84	Elevated Procoagulant Endothelial and Tissue Factor Expressing Microparticles in Women with Recurrent Pregnancy Loss. PLoS ONE, 2013, 8, e81407.	2.5	38
85	Prothrombin Mumbai causes severe prothrombin deficiency due to a novel Cys90Ser mutation. Annals of Hematology, 2012, 91, 1667-1668.	1.8	4
86	Hereditary protein C deficiency in Indian patients with venous thrombosis. Annals of Hematology, 2012, 91, 1471-1476.	1.8	4
87	A novel ELISA for diagnosis of Glanzmann's thrombasthenia and the heterozygote carriers. Annals of Hematology, 2012, 91, 917-921.	1.8	3
88	Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients. Haemophilia, 2012, 18, 794-797.	2.1	23
89	Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis – A concise review. Thrombosis Research, 2011, 127, 505-512.	1.7	36
90	An improved, semi quantitative clot based assay for factor XIII. Haemophilia, 2011, 17, 718-720.	2.1	11

#	Article	IF	CITATIONS
91	Mutations in coagulation factor XIII subunit A in severe factor XIII deficiency patients: five novel mutations detected. Haemophilia, 2011, 17, e843-5.	2.1	10
92	Challenges of multiple mutations in individual patients with haemophilia. European Journal of Haematology, 2011, 86, 185-190.	2.2	7
93	Pathophysiology of acquired von Willebrand disease: a concise review. European Journal of Haematology, 2011, 87, 99-106.	2.2	53
94	Acquired hemophilia A: Diagnosis, aetiology, clinical spectrum and treatment options. Autoimmunity Reviews, 2011, 10, 311-316.	5.8	103
95	Response to the letter of Casserta et al. Acquired hemophilia a following influenza vaccination. Autoimmunity Reviews, 2011, 11, 75.	5.8	0
96	Delayed vitamin K deficiency as a cause of bleeding: still a concern in the 21st century!. Blood Coagulation and Fibrinolysis, 2010, 21, 608-610.	1.0	4
97	Protein C (PROC) gene mutations in two Indian families with purpura fulminans. Annals of Hematology, 2010, 89, 835-836.	1.8	7
98	<i>JAK2</i> Mutations Across a Spectrum of Venous Thrombosis Cases: Table 1. American Journal of Clinical Pathology, 2010, 134, 82-85.	0.7	66
99	Molecular pathology of haemophilia A in Indian patients: Identification of 11 novel mutations. Clinica Chimica Acta, 2010, 411, 2004-2008.	1.1	7
100	Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors. Clinical Reviews in Allergy and Immunology, 2009, 37, 58-66.	6.5	46
101	Antiphospholipid antibodies in haemophilia patients with severe bleeding tendency: cause, consequence or a consequential cause?. Haemophilia, 2009, 15, 1104-1108.	2.1	6
102	Double mutations causing haemophilia B: a double whammy!. British Journal of Haematology, 2009, 145, 433-435.	2.5	11
103	REVIEW ARTICLE: Antiâ€phospholipid Antibodies and Other Immunological Causes of Recurrent Foetal Loss – A Review of Literature of Various Therapeutic Protocols. American Journal of Reproductive Immunology, 2009, 62, 9-24.	1.2	31
104	Novel mutations in GP IIb gene in Glanzmann's thrombasthenia from India. Platelets, 2009, 20, 35-40.	2.3	13
105	Novel Mutations in Factor IX Gene From Western India With Reference to Their Phenotypic and Haplotypic Attributes. Journal of Pediatric Hematology/Oncology, 2009, 31, 157-160.	0.6	7
106	Utility of an exon 14Bsll polymorphism for improved genetic diagnosis of hemophilia A in Indian population. Prenatal Diagnosis, 2008, 28, 920-922.	2.3	3
107	A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 137, 136-140.	1.1	15
108	Successful Pregnancy Outcome in Women With Bad Obstetric History and Recurrent Fetal Loss Due to Thrombophilia: Effect of Unfractionated Heparin and Low—Molecular Weight Heparin. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 174-179.	1.7	14

#	Article	IF	CITATIONS
109	Reduced Clinical Severity in a Mutationally Well-Characterized Cohort of Severe Hemophilia With Associated Thrombophilia. American Journal of Clinical Pathology, 2008, 130, 84-87.	0.7	11
110	A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia. Haematologica, 2008, 93, 797-798.	3.5	11
111	Thrombophilic dimension of recurrent fetal loss in Indian patients. Blood Coagulation and Fibrinolysis, 2008, 19, 581-584.	1.0	18
112	Thrombophilia and unexplained pregnancy loss in Indian patients. The National Medical Journal of India, 2008, 21, 116-9.	0.3	11
113	Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders. Haemophilia, 2007, 13, 172-177.	2.1	24
114	Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. British Journal of Haematology, 2007, 138, 541-544.	2.5	80
115	First-trimester prenatal diagnosis in haemophilia A and B families—10 years experience from a centre in India. Prenatal Diagnosis, 2006, 26, 1015-1017.	2.3	28
116	Mutations in GPIIIa molecule as a cause for Glanzmann thrombasthenia in Indian patients. Journal of Thrombosis and Haemostasis, 2005, 3, 482-488.	3.8	26
117	Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia, 2004, 10, 58-62.	2.1	50
118	Combination of thrombophilia markers in acute myocardial infarction of the young. Indian Journal of Medical Sciences, 2004, 58, 381-8.	0.1	9
119	An ELISA Assay for the Detection of Factor VIII Antibodies – Comparison with the Conventional Bethesda Assay in a Large Cohort of Haemophilia Samples. Acta Haematologica, 2003, 109, 18-22.	1.4	30
120	Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function. Platelets, 2003, 14, 351-354.	2.3	12
121	Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer. Blood Coagulation and Fibrinolysis, 2003, 14, 493-497.	1.0	26
122	Prenatal diagnosis in a haemophilia A family by both factor VIII activity and antigen measurements. Journal of the Association of Physicians of India, The, 2003, 51, 916-8.	0.0	1
123	First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia, 2002, 8, 776-780.	2.1	34
124	Combined factor VIII and IX deficiency in a family. International Journal of Laboratory Hematology, 2001, 23, 201-204.	0.2	8
125	Development of inhibitors in patients with haemophilia from India. Haemophilia, 2001, 7, 273-278.	2.1	43
126	Hereditary thrombophilia as a cause of Budd-Chiari syndrome: A study from Western India. Hepatology, 2001, 34, 666-670.	7.3	117

#	Article	IF	CITATIONS
127	Venous Thromboembolism in Young Patients From Western India: A Study. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 158-165.	1.7	62
128	Carrier detection and prenatal diagnosis in families with haemophilia. The National Medical Journal of India, 2001, 14, 81-3.	0.3	9
129	Combined factor V and VIII deficiency in Indian population. Haemophilia, 2000, 6, 504-507.	2.1	30
130	St 14 (DX S52) VNTR polymorphism in the Indian population and its application in carrier detection and prenatal diagnosis of haemophilia A families. Haematologia, 2000, 30, 203-207.	0.3	5
131	Epsilon-Aminocaproic Acid Inhibits the Activity of Factor VIII Inhibitors in Patients with Severe Haemophilia A in vivo and in vitro. Acta Haematologica, 2000, 103, 67-72.	1.4	8
132	Carrier detection in haemophilia A families: comparison of conventional coagulation parameters with DNA polymorphism analysis - first report from India. Haemophilia, 1999, 5, 243-246.	2.1	13
133	Molecular characterization of haemophilia A & B in Indians. Haemophilia, 1998, 4, 802-805.	2.1	9
134	Factor V Leiden Mutation and Budd-Chiari Syndrome. Blood, 1998, 92, 1838-1839.	1.4	11
135	Prenatal diagnosis of haemophilia: a preliminary report. The National Medical Journal of India, 1998, 11, 218-9.	0.3	1
136	Acquired inhibitor to factor VIII: report of two unusual cases. Haemophilia, 1997, 3, 212-214.	2.1	3
137	Factor VIII and IX gene polymorphisms and carrier analysis in Indian population. , 1997, 54, 271-275.		37
138	Inherited deficiency of multiple vitamin K-dependent coagulation factors and coagulation inhibitors presenting as hemorrhagic diathesis, mental retardation, and growth retardation. , 1996, 52, 67-67.		8